J.P. Morgan
Illumina CEO Jacob Thaysen told JPMorgan analysts that clinical consumables, NovaSeq X adoption will anchor company’s near-term outlook amid muted academic demand.
GE HealthCare CEO Arduini believes the imaging market is large enough to accommodate multiple players as adoption progresses, describing photon-counting CT as a long-cycle transition rather than a near-term shift.
While several competitors are developing or launching patch pumps, Insulet CEO McEvoy described Omnipod as differentiated by both technology and manufacturing scale. She said the company has invested roughly $3bn across R&D and manufacturing.
Siemens Healthineers expects to grow revenue by mid-single digits in fiscal 2026, assuming no contribution from China for a second consecutive year.
The market is assessing how the blocked JenaValve transaction affects Edwards Lifesciences’ longer-range growth, particularly following targets laid out at the company’s December 2025 investor day.
Johnson & Johnson expects a planned orthopedics separation to unfold over time, with a potential spin-off in the second half of 2027, drawing on experience from its earlier consumer health carve-out to guide execution.
Medtronic CEO Geoffrey Martha said tuck-in deals for Medtronic would typically be in the low to mid-single-digit billions. While no timing or targets were disclosed, CFO Thierry Pieton said the company has the balance sheet strength to pursue acquisitions without changing its capital return strategy
An uptick in deals, venture financings and biopharma stock prices could set a boisterous mood for the pharmaceutical industry’s annual business meeting in San Francisco.
Becton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.
Exec Chat: Dexcom’s COO Jake Leach joined a panel discussion on the future of biosensing at CES 2024, where biowearables and glucose tech ranked among hot topics. He also spoke to Medtech Insight about plans for the company’s new CGM called Stelo, designed for people with type 2 diabetes who do not use insulin, Dexcom’s work with Apple to enable CGM users, and non-invasive monitoring prospects.
Exec Chat: UK consumer feedback has led to enhancements to the Lingo biowearable’s companion app to provide deeper, more personalized insight on the meaning of glucose spikes, as well as weeklong challenges to encourage healthy behavioral changes. While awaiting FDA clearance for a planned 2024 launch of Lingo stateside, Abbott also is exploring ways of accessorizing the Lingo sensor to make it more fashionable. Lingo Biowearables leaders Olivier Ropars and Ben Fohner discuss.
Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.
The two medtech giants – both of which will soon be releasing new robotic systems – spoke about growth targets and opportunities going into 2024.
Nevro will lay off 63 people to save at least $14m a year. Most of those savings will be reinvested to cover increases in normal operating costs, merit pay increases and other expenses related to the recent acquisition of Vyrsa.
For Illumina, the past year has been mostly a nightmare of its making. However, with Grail’s divestiture on the cards for 2024, stability may soon return to the company.
The three genomics players all announced preliminary results prior to speaking, and all had more news to add about their recent success and their plans to grow the demand for cancer diagnostics.
The company has recorded impressive growth over the past year and issued strong guidance for the next. It has also announced plans for a new glucose monitor specifically targeting type II diabetics.